Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss	$ (2,320)	$ (2,573)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of patent portfolio	1,027	1,598
Change in fair value of investment	(345)
Change in fair value of warrant liabilities	259	(2,055)
Stock-based compensation	13	353
Depreciation expenses	2	1
Realized loss on marketable securities	303
Unrealized gain on marketable securities	(262)	62
Changes in assets and liabilities:
Prepaid expenses and other assets	93	271
Accounts payable and accrued expenses	(75)	(320)
Accrued salaries and benefits	(177)	(111)
Deferred revenue	(932)	3,812
Accrued lease liabilities	(133)	(133)
Net cash (used in) provided by operating activities	(2,547)	905
Cash flows from investing activities
Purchase of marketable securities	(11,283)	(15,707)
Purchase of property and equipment		(3)
Sale of marketable securities	12,533	12,070
Investment in Hoth Therapeutics, Inc.	(675)
Net cash provided by (used in) investing activities	575	(3,640)
Cash flows from financing activities
Cash paid for cancellation of common stock		(4)
Cash from issuance common stock, net of offering cost	2,095	2,140
Proceeds from exercise of warrants		760
Repurchase of restricted stock units to pay for employee withholding taxes	(24)
Net cash provided by financing activities	2,071	2,896
Net increase in cash and cash equivalents	99	161
Cash and cash equivalents, beginning of period	134	142
Cash and cash equivalents, end of period	233	303
Cash paid for interest and taxes	195
Non-cash investing and financing activities
Extinguishment of Series H Convertible Preferred Stock in connection with license agreement		31,480
Recognition of deferred revenue in connection with license agreement		$ 414